Bristol takes its bispecific conjugate into lung cancer
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
Concentra picks up a new Cargo
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
Bristol goes pivotal with SystImmune-partnered conjugate
The first global pivotal trial will be in first-line triple-negative breast cancer.
DualityBio tries to float again
The group expects to raise nearly $170m.
Avenzo follows Bristol’s lead
The private group taps DualityBio for an EGFR x HER3 ADC.
